A Phase 3 interventional study of Interferon beta-1a and Placebo in Respiratory Distress Syndrome, Adult, sponsored by Faron Pharmaceuticals Ltd. Terminated at 71 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-30.
Sponsored by Faron Pharmaceuticals Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 217 studies in Respiratory Distress Syndrome with a site in France — 42 open to participants now, 44 under way, 7 of them phase 3. Respiratory Distress Syndrome · France.
Among the 217 studies in Respiratory Distress Syndrome with a site in France, this one is the 21st largest by enrollment of the 118 interventional ones that give a count, is one of 8 that started in 2015, is one of 25 in phase 3, and was the 50th registered.
1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →42 of the 217 studies in Respiratory Distress Syndrome with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages up to 17
Centre Hospitalier de la côte Basque · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 193 Respiratory Distress Syndrome studies recruiting now, 117 (61%) set no upper age limit and 48 (25%) stop at 75 or younger; 50 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
217 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 26 · Phase 4 5
First in 2002; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 301 is above the median of 60 across 822 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 50 across the 118 interventional studies, 80 across the 97 observational. Of the 144 that completed or were terminated, 4 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 217 have an industry lead sponsor. The 10 most frequent:
Faron Pharmaceuticals Ltd is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Faron Pharmaceuticals Ltd has 2 studies filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
13 of the studies in Respiratory Distress Syndrome with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03368092Phase 3University Hospital, Strasbourg, FranceInhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma | 2027-09-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06254313University Hospital, BordeauxThe Role of Cxcr4Hi neutrOPhils in InflueNza | 2026-12 |
| NCT05406570Hospices Civils de LyonPersonalized Tidal Volume in ARDS (VT4HEMOD) | 2026-12 |
| NCT06119516Assistance Publique - Hôpitaux de ParisTranspulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study. | 2027-04-04 |
Add all 13 to your calendar (.ics) → With an account.
Among the 217 studies in Respiratory Distress Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study effectiveness and safety of a new drug FP-1201-lyo (recombinant human interferon beta-1a) is compared to placebo. Investigation is conducted with patients who have acute respiratory distress syndrome (ARDS). The new drug is expected to reduce the time which a patient need to be on the ventilator and improve patient's chances of survival. Currently there are no approved drugs for treating moderate or severe ARDS patients.
This is a Phase III clinical study to investigate the efficacy and safety of FP-1201-lyo (recombinant human interferon [IFN] beta-1a) compared to placebo in patients diagnosed with moderate or severe acute respiratory distress syndrome (ARDS). Primary objective is to demonstrate the efficacy of FP-1201-lyo in improving the clinical course and outcome based on survival and need for mechanical ventilation. Currently there are no approved drugs for treating moderate or severe ARDS patients.
FP-1201-lyo is a lyophilised powder form of recombinant human IFN beta-1a reconstituted in water for injection and is administered intravenously.
Recombinant human IFN beta-1a is an approved treatment for patients for other indication and its safety profile in such patients is well characterised.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All patients must be intubated and mechanically ventilated to diagnose ARDS and be eligible for the study
Patient has a diagnosis of moderate or severe ARDS according to the Berlin definition of ARDS:
Hypoxaemia:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FP-1201-lyo 10 μg (Interferon beta-1a) will be administered once daily as an intravenous bolus injection for 6 days. Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection.
Drug: Interferon beta-1a
FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days. Investigational placebo product is lyophilisate for solution for injection which will be reconstituted in water for injection.
Drug: Placebo
Investigational drug
Also known as: FP-1201-lyo, Traumakine, ATC code L03AB07
Placebo for investigational drug
Also known as: FP-1201-lyo Placebo
Composite Endpoint (VFDsurv; All-cause Mortality and Number of Days Free of Mechanical Ventilation) at Day 28
VFDsurv is a composite measure of all-cause mortality and the number of days free of mechanical ventilation (VFDsurv) within 28 days among survivors. Ventilator-free days (VFDs) correspond to those days when unassisted breathing (UAB) was possible for a complete calendar day. UAB was defined as: spontaneously breathing with face mask, nasal prong oxygen or room air, T-piece breathing, tracheostomy mask breathing, CPAP less than or equal to 5 cmH2O without pressure support or intermittent mandatory ventilation assistance, use of CPAP or BIPAP solely for sleep apnoea management. A patient was reported as ventilator-free after 2 consecutive calendar days of unassisted breathing (a VFD value of 0 is assigned to patients who die without initiating UAB or who require more than 28 days of mechanical ventilation. All patients who die before Day28 are assigned a VFDsurv value of -1).
Time frame: Day 28
Efficacy Endpoint: All-cause Mortality
Fatalities, mortality all-causes from randomisation up to Day 28
Time frame: At Day 28
Efficacy Endpoint: Mortality in ICU
All-cause mortality for subjects who died in Intensive Care Units up to Day 28.
Time frame: Up to Day 28
Efficacy Endpoint: Mortality in Hospital
This is the number of subjects who died in hospital (i.e. outside of Intensive Care Units) up to Day 28.
Time frame: Up to Day 28
Other Secondary Efficacy Endpoints: Days Free of Organ Failure
The total number of days free of organ failure by Sequential Organ Failure Assessment (SOFA) methodology. Overall, the median number of days free of organ failure was 0 days in both the treatment groups.
Time frame: Day 28 or last day in intensive care unit [ICU] if patient has left the ICU earlier than Day 28
Other Secondary Efficacy Endpoints: Days Free of Renal Support
Days without renal support (any renal support was documented). Overall, the median number of days free of renal support was 28 days in the active group and 27 days in the placebo group.
Time frame: Day 28
Other Secondary Efficacy Endpoints: Days Free of Vasoactive Support
Days without vasoactive support. The vasoactive support included catecholamine and non-catecholamine vasopressors, inotropes and vasodilating agents. Overall, the median number of days free of vasoactive support was 20 days in the active group and 21 days in the placebo group.
Time frame: Day 28
Other Secondary Efficacy Endpoint: Days Free of Mechanical Ventilation
The total number of days free of mechanical ventilation has been derived from the Patient Status report recorded on each day during the 28-day period. Patients who died during this period have been assigned a value of zero. This variable differs from the calculated "Ventilation Free Days (VFD) endpoint, which contribute to the VDFsurv primary efficacy endpoint as it require additional conditions of unassisted breathing (UAB) to be met.
Time frame: Day 28
Other Secondary Efficacy Endpoints: Number of ICU-free Days
Number of Intensive Care Unit free days up to Day 28, i.e. the patient is no longer receiving care in ICU. Patients who die during this period have been assigned a value of zero for the number of ICU care free days.
Time frame: Day 28
Other Secondary Efficacy Endpoints: Number of Days in Hospital
Hospitalisation days (including the stay at Intensive Care Units). Patients who died during this period have been assigned a value of 28 for the number of days in ICU or in hospital.
Time frame: Day 28
Evaluation of Safety: Adverse Events and Deaths
Adverse events (AE) up to Day 28. Per protocol, AEs occurring after Day 28 if the investigator considered a causal relationship with the study drug as well as all deaths up to Day 360 were reported. Treatment-emergent AEs (TEAEs) were defined as AEs that begins or worsens in intensity after at least one dose of study drug has been administered. Serious AEs (SAEs) were defined as any untoward medical occurrence that at any dose resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was an important medical event.
Time frame: AEs up to Day 28, only related after Day 28 and deaths up to Day 360
Efficacy Endpoint: Presence of Neutralising Antibodies to IFN Beta-1a
The immunological response to FP-1201-lyo was assessed by monitoring presence of anti-drug binding antibodies (BAbs) and neutralising antibodies (NAbs) to IFN beta-1a on pre-dose Day 1 and at Day 28, the last day in ICU or early termination (if earlier). The BAbs were determined first, and if present, the NAbs were also determined. Presence of BAbs and NAbs were summarised categorically, using positive/negative classification.
Time frame: Baseline and Day 28 (or last day in intensive care unit [ICU] or at withdrawal, if earlier)
Efficacy Endpoint: Evaluation of Pharmacodynamic (PD) Using Myxovirus Resistance Protein A (MxA) Biomarker
Evaluation of MxA biomarker change from baseline to D14 between treatments arms over time.
Time frame: From baseline to Day 14
Long-term Efficacy Endpoint: Change in Quality of Life From Baseline to Day 180
Quality of Life was assessed through EQ-5D-3L (EuroQol 5-Dimensions 3-Levels questionnaire). An EQ Visual Analogue Scale (VAS) total score (ranging from 0-100) was measured (0= Worst imaginable health state, 100= Best imaginable health state). The EQ-5D-3L VAS scores are numerically summarised as change from pre-dose (Day 1) to long term follow-up (Day 180 visit).
Time frame: Change from baseline to Day 180
Long-term Efficacy Endpoints Relating to Respiratory Functioning (FEV1)
Measuring FEV1 (forced expiratory volume in 1 second) assessed pulmonary function (airway obstruction, bronchoconstriction or bronchodilation). FEV1 is the volume exhaled during the first second of a forced expiratory manoeuvre, starting from the level of total lung capacity.
Time frame: Day 180
Long-term Efficacy Endpoints Relating to Neurological Functioning (6MWT)
The 6-minute walk test (6MWT) measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. According to the ERS/ATS technical standard to which the 6MWT was done, the walk test is done twice and the best result is used. It is an evaluation of the global and integrated responses of all systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood and neuromuscular units and muscle metabolism. The self-paced 6MWT assesses the sub- maximal level of functional capacity and will better reflect the functional exercise level for daily activities. ANOVA parameters estimates (LS Means and 90 % conf.interval) for the overall treatment difference was analysed.
Time frame: Day 180
Evaluation of Safety: Vital Signs - Heart Rate
Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point. No statistical analyses were made for vital signs.
Time frame: From baseline to Last Observation Performed (Day 28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)
Evaluation of Safety: Vital Signs - Body Temperature
Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point. No statistical analyses were made for vital signs.
Time frame: From baseline to Last Observation Performed (Day 28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)
Evaluation of Safety: Vital Signs - Blood Pressure
Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point. No statistical analyses were made for vital signs.
Time frame: From baseline to Last Observation Performed (Day 28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)
Evaluation of Safety: Physical Examination
Physical examination data (covering the major body systems; general appearance, head \[ear, nose and throat\], cardiovascular, eyes, respiratory, abdomen, urogenital, musculoskeletal, neurological, lymph nodes and skin) were categorized as "normal"; "abnormal, not clinically significant;" "abnormal, clinically significant" or "not done". Physical examinations were performed at Screening, then at the Last day in ICU and Day 28 (Out of ICU) or Early Termination, from which the last observation performed is derived. The changes from baseline to the last observations performed are categorized as "no change", "change clinically significant"; "change not clinically significant", "not done".
Time frame: From baseline to Last Observation Performed (D28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)
Evaluation of Safety: Laboratory Results
Laboratory safety assessments of biochemistry, haematology and urinalysis were performed daily during the stay at ICU. Laboratory data were classified according to normal ranges as out of range (OOR; not clinically significant), OOR (clinically significant), or OOR (clinically significant and an AE). Laboratory test results were summarised by actual results by baseline and last observation period.
Time frame: From baseline to Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)
Evaluation of Pharmacoeconomics: Days Free of Organ Failure
Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.
Time frame: Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)
Evaluation of Pharmacoeconomics: Days Free of Renal Support
Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.
Time frame: Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)
Evaluation of Pharmacoeconomics: Days Free of Vasoactive Support
Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.
Time frame: Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)
Evaluation of Pharmacoeconomics: Days Free of Mechanical Ventilation
Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.
Time frame: Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)
Evaluation of Pharmacoeconomics: Number of ICU-free Days
Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.
Time frame: Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)
Evaluation of Pharmacoeconomics: Number of Days in Hospital
Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.
Time frame: Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)
Exploratory Variables Relating to Efficacy: Composite Endpoint (Mortality and Days Free of Mechanical Ventilation) at Day 90
Composite endpoint including mortality and days free of mechanical ventilation (VFDsurv) within 90 days among survivors. Ventilation Free Survival at Day 90 has been classified as Dead, Alive but on a ventilator and Alive and breathing unassisted
Time frame: Within 90 days
Change in the Treatment-specific Exploratory Biomarker Cluster of Differentiation 73 (CD73) Concentration
Evaluation of Cluster of differentiation 73 (CD73) change from baseline to D14 between treatments arms over time.
Time frame: From baseline to Day 14
Changes in Levels of Potential Inflammatory Markers (PIMs)
Evaluation of potential inflammatory markers (PIMs) change from baseline to D14 between treatments arms over time. Potential biomarkers included IL-1ra, IL-6, FGF basic, IP-10 and TNF-α.
Time frame: From baseline to Day 14
Pharmacogenetic Analysis
An optional genetic sample was analysed for subjects based on a separate consent. A carrier frequency was analysed for a C/T polymorphism (rs9984723) located in the 3'PRIME_UTR/intron region of IFNAR2-gene, which encodes the beta chain for the IFN-alpha/beta receptor and encompasses a regulatory motif for the glucocorticoid receptor. Biomarker responders were defined by a 3-fold elevation in MxA and a 2-fold in CD73 in comparison to baseline.
Time frame: Anytime from baseline to Day 28
Exploratory, Extended Long-term Follow-up: Overall Mortality at Day 360
Fatalities; as the study was terminated early, the assessment time point for mortality at Day 360 was not reached. Therefore only the overall mortality at study termination is presented.
Time frame: Day 360 /termination of study
Extended Long-term Follow-up Exploratory Endpoint: Change in Quality of Life From Baseline to Day 360
Quality of Life was assessed through EQ-5D-3L (EuroQol 5-Dimensions 3-Levels questionnaire). An EQ Visual Analogue Scale (VAS) total score (ranging from 0-100) was measured (0= Worst imaginable health state, 100= Best imaginable health state). The EQ-5D-3L VAS scores are numerically summarised as change from pre-dose (Day 1) to extended long term follow-up (Day 360 visit).
Time frame: Change from baseline to Day 360
Neurological Functioning (6MWT) at Extended Long-term Follow-up
The 6-minute walk test (6MWT) measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. According to the ERS/ATS technical standard to which the 6MWT was done, the walk test is done twice and the best result is used. It is an evaluation of the global and integrated responses of all systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood and neuromuscular units and muscle metabolism. The self-paced 6MWT assesses the sub- maximal level of functional capacity and will better reflect the functional exercise level for daily activities. ANOVA parameters estimates (LS Means and 90 % confidence intervals) for the overall treatment difference was analysed.
Time frame: Day 360
Extended Long-term Follow-up Endpoint: Respiratory Functioning (FEV1) at Day 360
Measuring FEV1 (forced expiratory volume in 1 second) assessed pulmonary function (airway obstruction, bronchoconstriction or bronchodilation). FEV1 is the volume exhaled during the first second of a forced expiratory manoeuvre, starting from the level of total lung capacity.
Time frame: Day 360
| Milestone | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Started | 144 | 152 |
| Subjects randomised | 146 | 155 |
| Short-term follow-up (day 28) | 105 | 115 |
| Long-term follow-up (day 90) | 96 | 101 |
| Long-term follow-up (day 180) | 73 | 74 |
| Completed | 51 | 49 |
| Not completed | 93 | 103 |
| Withdrew: Death | 51 | 53 |
| Withdrew: Lost to follow-up, withdrawal of consent | 4 | 7 |
| Withdrew: Early termination of study | 38 | 43 |
VFDsurv is a composite measure of all-cause mortality and the number of days free of mechanical ventilation (VFDsurv) within 28 days among survivors. Ventilator-free days (VFDs) correspond to those days when unassisted breathing (UAB) was possible for a complete calendar day. UAB was defined as: spontaneously breathing with face mask, nasal prong oxygen or room air, T-piece breathing, tracheostomy mask breathing, CPAP less than or equal to 5 cmH2O without pressure support or intermittent mandatory ventilation assistance, use of CPAP or BIPAP solely for sleep apnoea management. A patient was reported as ventilator-free after 2 consecutive calendar days of unassisted breathing (a VFD value of 0 is assigned to patients who die without initiating UAB or who require more than 28 days of mechanical ventilation. All patients who die before Day28 are assigned a VFDsurv value of -1).
| Days | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Composite Endpoint (VFDsurv; All-cause Mortality and Number of Days Free of Mechanical Ventilation) at Day 28 | 10 (-1 to 26) | 8.5 (-1 to 26) |
Fatalities, mortality all-causes from randomisation up to Day 28
| percentage of subjects | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Efficacy Endpoint: All-cause Mortality | 26.4 (19 to 34) | 23 (17 to 31) |
All-cause mortality for subjects who died in Intensive Care Units up to Day 28.
| percentage of subjects | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Efficacy Endpoint: Mortality in ICU | 25.7 (19 to 34) | 23.0 (17 to 31) |
This is the number of subjects who died in hospital (i.e. outside of Intensive Care Units) up to Day 28.
| Participants | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Efficacy Endpoint: Mortality in Hospital | 1 | 0 |
The total number of days free of organ failure by Sequential Organ Failure Assessment (SOFA) methodology. Overall, the median number of days free of organ failure was 0 days in both the treatment groups.
| Days | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Other Secondary Efficacy Endpoints: Days Free of Organ Failure | 0 (0 to 28) | 0 (0 to 28) |
Days without renal support (any renal support was documented). Overall, the median number of days free of renal support was 28 days in the active group and 27 days in the placebo group.
| Days | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Other Secondary Efficacy Endpoints: Days Free of Renal Support | 28 (0 to 28) | 27 (0 to 28) |
Days without vasoactive support. The vasoactive support included catecholamine and non-catecholamine vasopressors, inotropes and vasodilating agents. Overall, the median number of days free of vasoactive support was 20 days in the active group and 21 days in the placebo group.
| Days | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Other Secondary Efficacy Endpoints: Days Free of Vasoactive Support | 20 (0 to 28) | 21 (1 to 28) |
The total number of days free of mechanical ventilation has been derived from the Patient Status report recorded on each day during the 28-day period. Patients who died during this period have been assigned a value of zero. This variable differs from the calculated "Ventilation Free Days (VFD) endpoint, which contribute to the VDFsurv primary efficacy endpoint as it require additional conditions of unassisted breathing (UAB) to be met.
| Days | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Other Secondary Efficacy Endpoint: Days Free of Mechanical Ventilation | 10 (0 to 26) | 9 (0 to 26) |
Number of Intensive Care Unit free days up to Day 28, i.e. the patient is no longer receiving care in ICU. Patients who die during this period have been assigned a value of zero for the number of ICU care free days.
| Days | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Other Secondary Efficacy Endpoints: Number of ICU-free Days | 6 (0 to 24) | 3.5 (0 to 24) |
Hospitalisation days (including the stay at Intensive Care Units). Patients who died during this period have been assigned a value of 28 for the number of days in ICU or in hospital.
| Days | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Other Secondary Efficacy Endpoints: Number of Days in Hospital | 28 (8 to 28) | 28 (8 to 28) |
Adverse events (AE) up to Day 28. Per protocol, AEs occurring after Day 28 if the investigator considered a causal relationship with the study drug as well as all deaths up to Day 360 were reported. Treatment-emergent AEs (TEAEs) were defined as AEs that begins or worsens in intensity after at least one dose of study drug has been administered. Serious AEs (SAEs) were defined as any untoward medical occurrence that at any dose resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was an important medical event.
| Participants | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Subjects with TEAE | 130 | 132 |
| Subjects with AE considered related to study drug | 41 | 33 |
| Subjects with SAE | 77 | 77 |
| Death | 51 | 53 |
The immunological response to FP-1201-lyo was assessed by monitoring presence of anti-drug binding antibodies (BAbs) and neutralising antibodies (NAbs) to IFN beta-1a on pre-dose Day 1 and at Day 28, the last day in ICU or early termination (if earlier). The BAbs were determined first, and if present, the NAbs were also determined. Presence of BAbs and NAbs were summarised categorically, using positive/negative classification.
| Participants | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Presence of BAbs to IFN β-1a at baseline | 2 | 2 |
| Presence of BAbs to IFN β-1a at Day28 | 0 | 1 |
| Presence of NAbs to IFN β-1a at baseline | 1 | 0 |
| Presence of NAbs to IFN β-1a at Day28 | 0 | 0 |
Evaluation of MxA biomarker change from baseline to D14 between treatments arms over time.
| ng/ml | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Efficacy Endpoint: Evaluation of Pharmacodynamic (PD) Using Myxovirus Resistance Protein A (MxA) Biomarker | 31.8 ± 63.3 | 7.8 ± 28.8 |
Quality of Life was assessed through EQ-5D-3L (EuroQol 5-Dimensions 3-Levels questionnaire). An EQ Visual Analogue Scale (VAS) total score (ranging from 0-100) was measured (0= Worst imaginable health state, 100= Best imaginable health state). The EQ-5D-3L VAS scores are numerically summarised as change from pre-dose (Day 1) to long term follow-up (Day 180 visit).
| change score on a scale | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Long-term Efficacy Endpoint: Change in Quality of Life From Baseline to Day 180 | -10 (-55 to 70) | -5 (-60 to 91) |
Measuring FEV1 (forced expiratory volume in 1 second) assessed pulmonary function (airway obstruction, bronchoconstriction or bronchodilation). FEV1 is the volume exhaled during the first second of a forced expiratory manoeuvre, starting from the level of total lung capacity.
| %FEV1 | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Long-term Efficacy Endpoints Relating to Respiratory Functioning (FEV1) | 81.2 ± 21.1 | 79.5 ± 29.6 |
The 6-minute walk test (6MWT) measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. According to the ERS/ATS technical standard to which the 6MWT was done, the walk test is done twice and the best result is used. It is an evaluation of the global and integrated responses of all systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood and neuromuscular units and muscle metabolism. The self-paced 6MWT assesses the sub- maximal level of functional capacity and will better reflect the functional exercise level for daily activities. ANOVA parameters estimates (LS Means and 90 % conf.interval) for the overall treatment difference was analysed.
| maximum distance walked (meters) | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Long-term Efficacy Endpoints Relating to Neurological Functioning (6MWT) | 449 ± 174 | 424 ± 156 |
Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point. No statistical analyses were made for vital signs.
| bpm | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Heart Rate, bpm : Pre-Dose | 93.4 ± 22.2 | 94.8 ± 22.5 |
| Heart Rate, bpm : LOP | 92.5 ± 18.3 | 92.7 ± 19.0 |
Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point. No statistical analyses were made for vital signs.
| degrees Celsius | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Body Temperature, degrees C : Pre-Dose | 37.1 ± 1.1 | 37.2 ± 1.1 |
| Body Temperature, degrees C : LOP | 36.9 ± 0.9 | 36.8 ± 0.7 |
Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point. No statistical analyses were made for vital signs.
| mmHg | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Systolic Blood Pressure, mmHg: Pre-Dose | 114.6 ± 20.4 | 110.2 ± 18.0 |
| Systolic Blood Pressure, mmHg : LOP | 124.3 ± 22.8 | 120.3 ± 26.2 |
| Diastolic Blood Pressure, mmHg : Pre-Dose | 58.9 ± 12.9 | 55.6 ± 9.7 |
| Diastolic Blood Pressure, mmHg : LOP | 65.1 ± 14.8 | 62.6 ± 13.8 |
| Mean Arterial Pressure, mmHg : Pre-Dose | 76.5 ± 13.9 | 73.6 ± 11.2 |
| Mean Arterial Pressure, mmHg : LOP | 82.7 ± 15.5 | 80.8 ± 16.6 |
Physical examination data (covering the major body systems; general appearance, head \[ear, nose and throat\], cardiovascular, eyes, respiratory, abdomen, urogenital, musculoskeletal, neurological, lymph nodes and skin) were categorized as "normal"; "abnormal, not clinically significant;" "abnormal, clinically significant" or "not done". Physical examinations were performed at Screening, then at the Last day in ICU and Day 28 (Out of ICU) or Early Termination, from which the last observation performed is derived. The changes from baseline to the last observations performed are categorized as "no change", "change clinically significant"; "change not clinically significant", "not done".
| Participants | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| General Appearance — No change | 59 | 66 |
| General Appearance — Change, Clinically Significant | 8 | 9 |
| General Appearance — Change, Not Clinically Significant | 8 | 8 |
| General Appearance — Not done | 33 | 34 |
| General Appearance — Not available/pt died | 36 | 35 |
| Ear, Nose and Throat — No change | 67 | 75 |
| Ear, Nose and Throat — Change, Clinically Significant | 2 | 1 |
| Ear, Nose and Throat — Change, Not Clinically Significant | 5 | 6 |
| Ear, Nose and Throat — Not done | 34 | 35 |
| Ear, Nose and Throat — Not available/pt died | 36 | 35 |
| Eyes — No change | 70 | 76 |
| Eyes — Change, Clinically Significant | 1 | 1 |
| Eyes — Change, Not Clinically Significant | 2 | 3 |
| Eyes — Not done | 35 | 36 |
| Eyes — Not available/pt died | 36 | 36 |
| Respiratory — No change | 27 | 30 |
| Respiratory — Change, Clinically Significant | 30 | 28 |
| Respiratory — Change, Not Clinically Significant | 21 | 26 |
| Respiratory — Not done | 30 | 33 |
| Respiratory — Not available/pt died | 36 | 35 |
| Abdomen — No change | 65 | 70 |
| Abdomen — Change, Clinically Significant | 3 | 2 |
| Abdomen — Change, Not Clinically Significant | 9 | 10 |
| Abdomen — Not done | 31 | 35 |
| Abdomen — Not available/pt died | 36 | 35 |
| Urogenital — No change | 67 | 72 |
| Urogenital — Change, Clinically Significant | 3 | 3 |
| Urogenital — Change, Not Clinically Significant | 6 | 4 |
| Urogenital — Not done | 32 | 38 |
| Urogenital — Not available/pt died | 36 | 35 |
| Musculoskeletal — No change | 59 | 63 |
| Musculoskeletal — Change, Clinically Significant | 11 | 8 |
| Musculoskeletal — Change, Not Clinically Significant | 5 | 9 |
| Musculoskeletal — Not done | 33 | 37 |
| Musculoskeletal — Not available/pt died | 36 | 35 |
| Neurological — No change | 49 | 55 |
| Neurological — Change, Clinically Significant | 18 | 14 |
| Neurological — Change, Not Clinically Significant | 8 | 13 |
| Neurological — Not done | 33 | 34 |
| Neurological — Not available/pt died | 36 | 36 |
| Lymph nodes — No change | 69 | 78 |
| Lymph nodes — Change, Clinically Significant | 0 | 0 |
| Lymph nodes — Change, Not Clinically Significant | 0 | 0 |
| Lymph nodes — Not done | 39 | 39 |
| Lymph nodes — Not available/pt died | 36 | 35 |
| Skin — No change | 64 | 64 |
| Skin — Change, Clinically Significant | 3 | 8 |
| Skin — Change, Not Clinically Significant | 5 | 8 |
| Skin — Not done | 36 | 37 |
| Skin — Not available/pt died | 36 | 35 |
| Cardiovascular — No change | 56 | 60 |
| Cardiovascular — Change, Clinically Significant | 9 | 8 |
| Cardiovascular — Change, Not Clinically Significant | 8 | 12 |
| Cardiovascular — Not done | 33 | 37 |
| Cardiovascular — Not available/pt died | 38 | 35 |
Laboratory safety assessments of biochemistry, haematology and urinalysis were performed daily during the stay at ICU. Laboratory data were classified according to normal ranges as out of range (OOR; not clinically significant), OOR (clinically significant), or OOR (clinically significant and an AE). Laboratory test results were summarised by actual results by baseline and last observation period.
| Participants | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Haemoglobin, Pre-Dose — Normal | 22 | 30 |
| Haemoglobin, Pre-Dose — OOR (NCS) | 103 | 107 |
| Haemoglobin, Pre-Dose — OOR (CS) | 19 | 14 |
| Haemoglobin, Pre-Dose — OOR (CS+AE) | 0 | 0 |
| Haemoglobin, Pre-Dose — Not available/pt died | 0 | 1 |
| Haemoglobin, LOP — Normal | 17 | 18 |
| Haemoglobin, LOP — OOR (NCS) | 100 | 117 |
| Haemoglobin, LOP — OOR (CS) | 23 | 16 |
| Haemoglobin, LOP — OOR (CS+AE) | 3 | 1 |
| Haemoglobin, LOP — Not available/pt died | 1 | 0 |
| Platelets, Pre-Dose — Normal | 85 | 91 |
| Platelets, Pre-Dose — OOR (NCS) | 43 | 42 |
| Platelets, Pre-Dose — OOR (CS) | 16 | 17 |
| Platelets, Pre-Dose — OOR (CS+AE) | 0 | 0 |
| Platelets, Pre-Dose — Not available/pt died | 0 | 2 |
| Platelets, LOP — Normal | 76 | 65 |
| Platelets, LOP — OOR (NCS) | 52 | 72 |
| Platelets, LOP — OOR (CS) | 10 | 10 |
| Platelets, LOP — OOR (CS+AE) | 5 | 5 |
| Platelets, LOP — Not available/pt died | 1 | 0 |
| Leucocytes, Pre-Dose — Normal | 40 | 58 |
| Leucocytes, Pre-Dose — OOR (NCS) | 72 | 56 |
| Leucocytes, Pre-Dose — OOR (CS) | 32 | 36 |
| Leucocytes, Pre-Dose — OOR (CS+AE) | 0 | 0 |
| Leucocytes, Pre-Dose — Not available/pt died | 0 | 2 |
| Leucocytes, LOP — Normal | 72 | 57 |
| Leucocytes, LOP — OOR (NCS) | 52 | 70 |
| Leucocytes, LOP — OOR (CS) | 15 | 21 |
| Leucocytes, LOP — OOR (CS+AE) | 3 | 4 |
| Leucocytes, LOP — Not available/pt died | 2 | 0 |
| Albumin, Pre-Dose — Normal | 17 | 17 |
| Albumin, Pre-Dose — OOR (NCS) | 83 | 106 |
| Albumin, Pre-Dose — OOR (CS) | 20 | 14 |
| Albumin, Pre-Dose — OOR (CS+AE) | 0 | 0 |
| Albumin, Pre-Dose — Not available/pt died | 24 | 15 |
| Albumin, LOP — Normal | 26 | 25 |
| Albumin, LOP — OOR (NCS) | 97 | 117 |
| Albumin, LOP — OOR (CS) | 18 | 9 |
| Albumin, LOP — OOR (CS+AE) | 1 | 0 |
| Albumin, LOP — Not available/pt died | 2 | 1 |
| Creatine Kinase, Pre-Dose — Normal | 59 | 62 |
| Creatine Kinase, Pre-Dose — OOR (NCS) | 32 | 45 |
| Creatine Kinase, Pre-Dose — OOR (CS) | 19 | 11 |
| Creatine Kinase, Pre-Dose — OOR (CS+AE) | 1 | 0 |
| Creatine Kinase, Pre-Dose — Not available/pt died | 33 | 34 |
| Creatine Kinase, LOP — Normal | 82 | 93 |
| Creatine Kinase, LOP — OOR (NCS) | 45 | 45 |
| Creatine Kinase, LOP — OOR (CS) | 11 | 8 |
| Creatine Kinase, LOP — OOR (CS+AE) | 2 | 0 |
| Creatine Kinase, LOP — Not available/pt died | 4 | 6 |
| Creatinine, Pre-Dose — Normal | 78 | 72 |
| Creatinine, Pre-Dose — OOR (NCS) | 41 | 50 |
| Creatinine, Pre-Dose — OOR (CS) | 23 | 28 |
| Creatinine, Pre-Dose — OOR (CS+AE) | 2 | 0 |
| Creatinine, Pre-Dose — Not available/pt died | 0 | 2 |
| Creatinine, LOP — Normal | 69 | 73 |
| Creatinine, LOP — OOR (NCS) | 56 | 64 |
| Creatinine, LOP — OOR (CS) | 13 | 14 |
| Creatinine, LOP — OOR (CS+AE) | 5 | 1 |
| Creatinine, LOP — Not available/pt died | 1 | 0 |
| Glucose, Pre-Dose — Normal | 56 | 53 |
| Glucose, Pre-Dose — OOR (NCS) | 76 | 85 |
| Glucose, Pre-Dose — OOR (CS) | 11 | 10 |
| Glucose, Pre-Dose — OOR (CS+AE) | 0 | 0 |
| Glucose, Pre-Dose — Not available/pt died | 1 | 4 |
| Glucose, LOP — Normal | 65 | 74 |
| Glucose, LOP — OOR (NCS) | 71 | 75 |
| Glucose, LOP — OOR (CS) | 7 | 3 |
| Glucose, LOP — OOR (CS+AE) | 0 | 0 |
| Glucose, LOP — Not available/pt died | 1 | 0 |
| Bilirubin, Pre-Dose — Normal | 88 | 106 |
| Bilirubin, Pre-Dose — OOR (NCS) | 37 | 33 |
| Bilirubin, Pre-Dose — OOR (CS) | 9 | 6 |
| Bilirubin, Pre-Dose — OOR (CS+AE) | 0 | 0 |
| Bilirubin, Pre-Dose — Not available/pt died | 10 | 7 |
| Bilirubin, LOP — Normal | 114 | 121 |
| Bilirubin, LOP — OOR (NCS) | 19 | 23 |
| Bilirubin, LOP — OOR (CS) | 4 | 3 |
| Bilirubin, LOP — OOR (CS+AE) | 6 | 5 |
| Bilirubin, LOP — Not available/pt died | 1 | 0 |
| AST, Pre-Dose — Normal | 57 | 52 |
| AST, Pre-Dose — OOR (NCS) | 50 | 70 |
| AST, Pre-Dose — OOR (CS) | 18 | 14 |
| AST, Pre-Dose — OOR (CS+AE) | 2 | 0 |
| AST, Pre-Dose — Not available/pt died | 17 | 16 |
| AST, LOP — Normal | 67 | 76 |
| AST, LOP — OOR (NCS) | 54 | 56 |
| AST, LOP — OOR (CS) | 8 | 11 |
| AST, LOP — OOR (CS+AE) | 11 | 7 |
| AST, LOP — Not available/pt died | 4 | 2 |
| ALT, Pre-Dose — Normal | 86 | 92 |
| ALT, Pre-Dose — OOR (NCS) | 37 | 43 |
| ALT, Pre-Dose — OOR (CS) | 9 | 9 |
| ALT, Pre-Dose — OOR (CS+AE) | 2 | 0 |
| ALT, Pre-Dose — Not available/pt died | 10 | 8 |
| ALT, LOP — Normal | 72 | 85 |
| ALT, LOP — OOR (NCS) | 52 | 46 |
| ALT, LOP — OOR (CS) | 8 | 12 |
| ALT, LOP — OOR (CS+AE) | 10 | 8 |
| ALT, LOP — Not available/pt died | 2 | 1 |
| Bicarbonate, Pre-Dose — Normal | 90 | 97 |
| Bicarbonate, Pre-Dose — OOR (NCS) | 44 | 47 |
| Bicarbonate, Pre-Dose — OOR (CS) | 8 | 7 |
| Bicarbonate, Pre-Dose — OOR (CS+AE) | 0 | 0 |
| Bicarbonate, Pre-Dose — Not available/pt died | 2 | 1 |
| Bicarbonate, LOP — Normal | 89 | 105 |
| Bicarbonate, LOP — OOR (NCS) | 47 | 41 |
| Bicarbonate, LOP — OOR (CS) | 7 | 6 |
| Bicarbonate, LOP — OOR (CS+AE) | 0 | 0 |
| Bicarbonate, LOP — Not available/pt died | 1 | 0 |
| Urine Protein, Pre-Dose — Normal | 52 | 54 |
| Urine Protein, Pre-Dose — OOR (NCS) | 67 | 73 |
| Urine Protein, Pre-Dose — OOR (CS) | 5 | 7 |
| Urine Protein, Pre-Dose — OOR (CS+AE) | 0 | 0 |
| Urine Protein, Pre-Dose — Not available/pt died | 20 | 18 |
| Urine Protein, LOP — Normal | 66 | 84 |
| Urine Protein, LOP — OOR (NCS) | 63 | 53 |
| Urine Protein, LOP — OOR (CS) | 10 | 7 |
| Urine Protein, LOP — OOR (CS+AE) | 0 | 1 |
| Urine Protein, LOP — Not available/pt died | 5 | 7 |
| Urine Glucose, Pre-Dose — Normal | 114 | 123 |
| Urine Glucose, Pre-Dose — OOR (NCS) | 9 | 7 |
| Urine Glucose, Pre-Dose — OOR (CS) | 0 | 3 |
| Urine Glucose, Pre-Dose — OOR (CS+AE) | 0 | 0 |
| Urine Glucose, Pre-Dose — Not available/pt died | 21 | 19 |
| Urine Glucose, LOP — Normal | 128 | 135 |
| Urine Glucose, LOP — OOR (NCS) | 9 | 10 |
| Urine Glucose, LOP — OOR (CS) | 1 | 0 |
| Urine Glucose, LOP — OOR (CS+AE) | 0 | 0 |
| Urine Glucose, LOP — Not available/pt died | 6 | 7 |
| Urine Blood, Pre-Dose — Normal | 48 | 53 |
| Urine Blood, Pre-Dose — OOR (NCS) | 67 | 75 |
| Urine Blood, Pre-Dose — OOR (CS) | 10 | 8 |
| Urine Blood, Pre-Dose — OOR (CS+AE) | 0 | 0 |
| Urine Blood, Pre-Dose — Not available/pt died | 19 | 16 |
| Urine Blood, LOP — Normal | 57 | 58 |
| Urine Blood, LOP — OOR (NCS) | 73 | 77 |
| Urine Blood, LOP — OOR (CS) | 9 | 10 |
| Urine Blood, LOP — OOR (CS+AE) | 0 | 0 |
| Urine Blood, LOP — Not available/pt died | 5 | 7 |
Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.
No measurements were reported for this outcome.
Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.
No measurements were reported for this outcome.
Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.
No measurements were reported for this outcome.
Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.
No measurements were reported for this outcome.
Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.
No measurements were reported for this outcome.
Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.
No measurements were reported for this outcome.
Composite endpoint including mortality and days free of mechanical ventilation (VFDsurv) within 90 days among survivors. Ventilation Free Survival at Day 90 has been classified as Dead, Alive but on a ventilator and Alive and breathing unassisted
| Participants | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Dead | 47 | 48 |
| Alive-on ventilator | 6 | 10 |
| Alive-breathing unassisted | 90 | 91 |
Evaluation of Cluster of differentiation 73 (CD73) change from baseline to D14 between treatments arms over time.
| ng/ml | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Change in the Treatment-specific Exploratory Biomarker Cluster of Differentiation 73 (CD73) Concentration | 6.2 ± 8.9 | 6.1 ± 7.9 |
Evaluation of potential inflammatory markers (PIMs) change from baseline to D14 between treatments arms over time. Potential biomarkers included IL-1ra, IL-6, FGF basic, IP-10 and TNF-α.
| pg/mL | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| IL-1ra | 1830 ± 5252 | 1699 ± 4565 |
| IL-6 | 63 ± 298 | 88 ± 584 |
| FGF basic | 37 ± 17 | 38 ± 20 |
| IP-10 | 1938 ± 3543 | 1762 ± 3894 |
| TNF-α | 68 ± 60 | 81 ± 148 |
An optional genetic sample was analysed for subjects based on a separate consent. A carrier frequency was analysed for a C/T polymorphism (rs9984723) located in the 3'PRIME_UTR/intron region of IFNAR2-gene, which encodes the beta chain for the IFN-alpha/beta receptor and encompasses a regulatory motif for the glucocorticoid receptor. Biomarker responders were defined by a 3-fold elevation in MxA and a 2-fold in CD73 in comparison to baseline.
| Participants | Biomarker Responder | Biomarker Non-responder |
|---|---|---|
| C-allele carrier | 21 | 26 |
| C-allele non-carrier | 12 | 47 |
Fatalities; as the study was terminated early, the assessment time point for mortality at Day 360 was not reached. Therefore only the overall mortality at study termination is presented.
| Participants | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Exploratory, Extended Long-term Follow-up: Overall Mortality at Day 360 | 51 | 53 |
Quality of Life was assessed through EQ-5D-3L (EuroQol 5-Dimensions 3-Levels questionnaire). An EQ Visual Analogue Scale (VAS) total score (ranging from 0-100) was measured (0= Worst imaginable health state, 100= Best imaginable health state). The EQ-5D-3L VAS scores are numerically summarised as change from pre-dose (Day 1) to extended long term follow-up (Day 360 visit).
| change score on a scale | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Extended Long-term Follow-up Exploratory Endpoint: Change in Quality of Life From Baseline to Day 360 | 0 (-59 to 35) | 0 (-80 to 86) |
The 6-minute walk test (6MWT) measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. According to the ERS/ATS technical standard to which the 6MWT was done, the walk test is done twice and the best result is used. It is an evaluation of the global and integrated responses of all systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood and neuromuscular units and muscle metabolism. The self-paced 6MWT assesses the sub- maximal level of functional capacity and will better reflect the functional exercise level for daily activities. ANOVA parameters estimates (LS Means and 90 % confidence intervals) for the overall treatment difference was analysed.
| maximal distance walked (meters) | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Neurological Functioning (6MWT) at Extended Long-term Follow-up | 475 ± 119 | 453 ± 190 |
Measuring FEV1 (forced expiratory volume in 1 second) assessed pulmonary function (airway obstruction, bronchoconstriction or bronchodilation). FEV1 is the volume exhaled during the first second of a forced expiratory manoeuvre, starting from the level of total lung capacity.
| %FEV1 | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Extended Long-term Follow-up Endpoint: Respiratory Functioning (FEV1) at Day 360 | 69.4 ± 31.8 | 72.0 ± 28.5 |
The overall use of concomitant glucocorticoids treatment in both study treatment groups (active and placebo) were analysed.
| percentage of participants | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| Use of concomitant glucocorticoids | 54.1 | 64.5 |
| Mortality, with concomitant glucocorticoids | 39.7 | 27.6 |
| Mortality, without concomitant glucocorticoids | 10.6 | 14.8 |
Collected over The Adverse Event (AE) reporting period extended up to study Day 28. In accordance with the protocol, the investigators reported AEs occurring after Day 28 only if the investigator considered a causal relationship with the study drug. All deaths were reported as SAEs throughout the study, up until Day 360.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FP-1201-lyo 10 μg | 51/144 (35.4%) | 77/144 (53.5%) | 109/144 (75.7%) |
| Placebo | 53/152 (34.9%) | 77/152 (50.7%) | 110/152 (72.4%) |
| Event | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| MULTI-ORGAN FAILUREGeneral disorders | 13/144 | 8/152 |
| CONDITION AGGRAVATEDGeneral disorders | 7/144 | 11/152 |
| RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders | 3/144 | 9/152 |
| PNEUMONIAInfections and infestations | 5/144 | 9/152 |
| SEPTIC SHOCKInfections and infestations | 7/144 | 5/152 |
| ACUTE RESPIRATORY DISTRESS SYNDROMERespiratory, thoracic and mediastinal disorders | 2/144 | 7/152 |
| SHOCK HAEMORRHAGICVascular disorders | 6/144 | 2/152 |
| HYPOXIARespiratory, thoracic and mediastinal disorders | 4/144 | 6/152 |
| CARDIAC ARRESTCardiac disorders | 4/144 | 5/152 |
| ACUTE KIDNEY INJURYRenal and urinary disorders | 1/144 | 5/152 |
| Event | FP-1201-lyo 10 μg | Placebo |
|---|---|---|
| PYREXIAGeneral disorders | 17/144 | 12/152 |
| ANAEMIABlood and lymphatic system disorders | 16/144 | 11/152 |
| ATRIAL FIBRILLATIONCardiac disorders | 9/144 | 15/152 |
| CONSTIPATIONGastrointestinal disorders | 11/144 | 14/152 |
| HYPERTENSIONVascular disorders | 11/144 | 10/152 |
| HYPERNATRAEMIAMetabolism and nutrition disorders | 9/144 | 7/152 |
| HEPATOCELLULAR INJURYHepatobiliary disorders | 9/144 | 8/152 |
| PNEUMONIAInfections and infestations | 8/144 | 4/152 |
| SEPSISInfections and infestations | 8/144 | 3/152 |
| PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders | 8/144 | 4/152 |
A total of 296 subjects received at least 1 dose of study treatment (301 subjects fulfilled all criteria and were randomly assigned in a 1:1 ratio to FP-1201-lyo and placebo, but 5 subjects were not dosed).The Full Analysis Set (FAS) consisted of the 296 randomised and treated subjects who received 1 or more doses study medication.
| Age, Categorical(Participants) | FP-1201-lyo 10 μg | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 89 | 101 | 190 |
| >=65 years | 55 | 51 | 106 |
| Age, Continuous(years) | FP-1201-lyo 10 μg | Placebo | Total |
|---|---|---|---|
| Mean | 58.3 ± 17.2 | 58.4 ± 14.0 | 58.4 ± 15.6 |
| Sex: Female, Male(Participants) | FP-1201-lyo 10 μg | Placebo | Total |
|---|---|---|---|
| Female | 42 | 61 | 103 |
| Male | 102 | 91 | 193 |
| Race/Ethnicity, Customized(Participants) | FP-1201-lyo 10 μg | Placebo | Total |
|---|---|---|---|
| Race — American Indian/Alaskan | 1 | 1 | 2 |
| Race — Native Arab | 4 | 2 | 6 |
| Race — Asian-Other | 1 | 2 | 3 |
| Race — Black | 4 | 5 | 9 |
| Race — Other or not reported | 35 | 36 | 71 |
| Race — White | 99 | 106 | 205 |
| Region of Enrollment(Participants) | FP-1201-lyo 10 μg | Placebo | Total |
|---|---|---|---|
| Belgium | 12 | 12 | 24 |
| Czechia | 1 | 1 | 2 |
| Finland | 15 | 15 | 30 |
| Italy | 18 | 19 | 37 |
| United Kingdom | 25 | 29 | 54 |
| France | 54 | 58 | 112 |
| Germany | 8 | 7 | 15 |
| Spain | 11 | 11 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2015 to primary completion in May 2018, 28 months.
Results were first posted in Mar 2020, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interferon beta-1a
Respiratory Distress Syndrome →
Faron Pharmaceuticals Ltd